Literature DB >> 17016631

Com-1/p8 acts as a putative tumour suppressor in prostate cancer.

Wen G Jiang1, Gaynor Davies, Tracey A Martin, Howard Kynaston, Malcolm D Mason, Oystein Fodstad.   

Abstract

Com-1, candidate of metastasis-1, also known as p8, is a recently discovered molecule with a putative role in determining the metastatic nature of cancer cells. We have investigated the expression of Com-1 in normal and malignant human prostate tissues and its molecular interaction within prostate cancer cells. The expression of Com-1 in human prostate tissues and prostate cancer cell lines was assessed at both the mRNA and protein levels, by RT-PCR and immunohistochemistry. The staining intensity of Com-1 was semiquantified using computer assisted image analysis. Full- length Com-1 cDNA was isolated from normal mammary tissues. Ribozyme transgenes that specifically target human Com-1 were constructed using the pEF6/V5-His vector. The growth of prostate cancer cells in vitro and tumour growth in vivo (athymic mice model) following Com-1 overexpression in prostate cancer cells were determined. In normal prostate tissues, the epithelial cells strongly stained Com-1, both in the cytoplasm and in the nucleus. In contrast, prostate cancer cells in tumour tissue showed substantially reduced Com-1 staining levels (p < 0.05 compared to normal cells for both cytoplasmic and nucleus staining), whereas the prostate cancer cell lines PC-3, DU145 and CA-HPV10 widely expressed Com-1. Transfection of these cells with hammerhead ribozyme transgenes resulted in the loss of expression of the Com-1 transcript. Using an in vitro invasion assay we found that the loss of Com-1 from prostate cancer cells increased their invasiveness. Knockout of Com-1 also resulted in the accelerated growth of all three cell lines. Forced overexpression of Com-1/ p8 in prostate cancer cells was able to reverse the changes in invasiveness and growth seen with the Com-1 knock-out cells. In a spontaneous tumour model, it was demonstrated that PC-3 cells with forced overexpression of Com-1 (PC-3com1Exp) had a significantly slower rate of growth compared with control cells (tumour size 36.6 +/- 31.2 vs 114.3 +/- 68.1 mm3, for tumours from PC-3com1Exp and control PC-3 cells, respectively, p = 0.0023). In conclusion, Com-1/p8 was expressed at lower levels in human prostate cancer cells compared with normal epithelial cells. Com-1/p8 levels are inversely correlated with the invasiveness and growth of prostate cancer cells in vitro and the overexpression of Com-1 reduced the growth of prostate tumours in vivo. Com-1/p8 is a potential tumour suppressor in human prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17016631

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  16 in total

1.  Expression of p8 in Human Oral Squamous Cell Carcinoma.

Authors:  Christopher Bingham; Douglas Dickinson; James Cray; Komal Koli; Kalu U E Ogbureke
Journal:  Head Neck Pathol       Date:  2014-08-26

2.  NUPR1 maintains autolysosomal efflux by activating SNAP25 transcription in cancer cells.

Authors:  Yanchao Mu; Xiaojie Yan; Ding Li; Dan Zhao; Lingling Wang; Xiaoyang Wang; Dan Gao; Jie Yang; Hua Zhang; Yanzhe Li; Yanan Sun; Yiliang Wei; Zhenfa Zhang; Xinzhong Chang; Zhi Yao; Shanshan Tian; Kai Zhang; Lance S Terada; Zhenyi Ma; Zhe Liu
Journal:  Autophagy       Date:  2017-12-31       Impact factor: 16.016

3.  A Dexamethasone-regulated Gene Signature Is Prognostic for Poor Survival in Glioblastoma Patients.

Authors:  Markus M Luedi; Sanjay K Singh; Jennifer C Mosley; Masumeh Hatami; Joy Gumin; Erik P Sulman; Frederick F Lang; Frank Stueber; Pascal O Zinn; Rivka R Colen
Journal:  J Neurosurg Anesthesiol       Date:  2017-01       Impact factor: 3.956

4.  Knockdown of NUPR1 inhibits the proliferation of glioblastoma cells via ERK1/2, p38 MAPK and caspase-3.

Authors:  Jun Li; Siyang Ren; Yongjian Liu; Zhigang Lian; Bin Dong; Yiqun Yao; Yinghui Xu
Journal:  J Neurooncol       Date:  2016-12-20       Impact factor: 4.130

5.  Nidogen 1 and Nuclear Protein 1: novel targets of ETV5 transcription factor involved in endometrial cancer invasion.

Authors:  Núria Pedrola; Laura Devis; Marta Llauradó; Irene Campoy; Elena Martinez-Garcia; Marta Garcia; Laura Muinelo-Romay; Lorena Alonso-Alconada; Miguel Abal; Francesc Alameda; Gemma Mancebo; Ramon Carreras; Josep Castellví; Sílvia Cabrera; Antonio Gil-Moreno; Xavier Matias-Guiu; Juan L Iovanna; Eva Colas; Jaume Reventós; Anna Ruiz
Journal:  Clin Exp Metastasis       Date:  2015-04-30       Impact factor: 5.150

6.  A role for Rac1 activity in malignant progression of sebaceous skin tumors.

Authors:  D Frances; N Sharma; R Pofahl; M Maneck; K Behrendt; K Reuter; T Krieg; C A Klein; I Haase; C Niemann
Journal:  Oncogene       Date:  2015-02-09       Impact factor: 9.867

7.  RAF265 inhibits the growth of advanced human melanoma tumors.

Authors:  Yingjun Su; Anna E Vilgelm; Mark C Kelley; Oriana E Hawkins; Yan Liu; Kelli L Boyd; Sara Kantrow; Ryan C Splittgerber; Sarah P Short; Tammy Sobolik; Snjezana Zaja-Milatovic; Kimberly Brown Dahlman; Katayoun I Amiri; Aixiang Jiang; Pengcheng Lu; Yu Shyr; Darrin D Stuart; Shawn Levy; Jeffrey A Sosman; Ann Richmond
Journal:  Clin Cancer Res       Date:  2012-02-20       Impact factor: 12.531

Review 8.  Stress-inducible protein p8 is involved in several physiological and pathological processes.

Authors:  Sandro Goruppi; Juan Lucio Iovanna
Journal:  J Biol Chem       Date:  2009-11-19       Impact factor: 5.157

9.  Developmentally regulated synthesis of p8, a stress-associated transcription cofactor, in diapause-destined embryos of Artemia franciscana.

Authors:  Zhijun Qiu; Thomas H MacRae
Journal:  Cell Stress Chaperones       Date:  2007       Impact factor: 3.667

10.  In silico cloning and characterization of p8 homolog cDNA from common urchin (Paracentrotus lividus).

Authors:  Jia-Qing Wang; Jin-Cheng Han; Dai-Zong Li; Lin-Chun Li
Journal:  Mol Biol Rep       Date:  2009-02-27       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.